Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Research, science & health

Huntington's disease: brain abnormalities detectable as early as the embryonic stage

Published on: 17/07/2020 Reading time: 1 min
image
Retour à la recherche

Huntington's disease is a genetic neurological disorder that generally appears in adulthood. Teams of researchers and clinicians at the Grenoble Institute of Neuroscience (Inserm/Grenoble Alpes University) and the Brain Institute (Inserm/Sorbonne University/CNRS/AP-HP) have discovered cerebral abnormalities in the brains of human embryos carrying the mutation responsible for Huntington's disease. This work, to be published in Science, raises questions about the mechanisms of silent progression of the disease, and when and how to treat patients in the future.

Although Huntington’s disease is a late-manifesting neurodegenerative disorder, both mouse studies and neuroimaging studies of presymptomatic mutation carriers suggest that Huntington’s disease might affect neurodevelopment. To determine whether this is actually the case, we examined tissue from human fetuses (13 weeks gestation) that carry the Huntington’s disease mutation. These tissues showed clear abnormalities in the developing cortex, including mislocalization of mutant huntingtin and junctional complex proteins, defects in neuroprogenitor cell polarity and differentiation, abnormal ciliogenesis, and changes in mitosis and cell cycle progression. We observed the same phenomena in Huntington’s disease mouse embryos, where we linked these abnormalities to defects in interkinetic nuclear migration of progenitor cells. Huntington’s disease thus has a neurodevelopmental component and is not solely a degenerative disease.

« C’est la première fois que des anomalies du développement cérébral sont mises en évidence dans cette maladie. De plus, celles-ci sont relativement importantes et étendues bien que nous ne soyons pas encore capables de déterminer leurs conséquences directes », clarifient Sandrine Humbert et Alexandra Durr qui ont dirigé ces travaux.

Mais pourquoi les porteurs de la mutation ne manifestent-ils alors aucun symptôme avant un âge avancé ? « À ce stade, nous posons l’hypothèse que le cerveau met très tôt en place des mécanismes de compensation qui permettent un fonctionnement normal. Il se pourrait d’ailleurs qu’il en soit de même chez les personnes porteuses de mutations associées à d’autres types de dégénérescence comme la maladie d’Alzheimer ou la sclérose latérale amyotrophique », précisent les chercheuses.

auteur à supprimer

Celles-ci vont maintenant poursuivre la description du développement cérébral chez des souris modèles de la maladie de Huntington, tenter de comprendre comment ces défauts précoces contribuent à la pathologie adulte, et comment la compensation de ces derniers pourrait être régulée pendant toute la période silencieuse sans symptômes. « Cette découverte a en outre des conséquences importantes sur la façon et le stade auxquels les traitements qui modifient le cours de la maladie doivent désormais être envisagés », concluent-elles.

auteur à supprimer

Sources

https://science.sciencemag.org/content/early/2020/07/15/science.aax3338

Our news on the subject

Épilepsie temporale : une nouvelle stratégie pour corriger l’activité électrique anormale
Temporal Lobe Epilepsy: A New Strategy to Correct Abnormal Electrical Activity
Many patients suffer from epilepsy that cannot be controlled by current medications. Surgical removal of epileptogenic brain regions is effective in only about half of cases, and not all patients are eligible for the procedure. For these individuals...
03.06.2026 Research, science & health
Stimuler les mitochondries pour doper la mémoire à long terme
Stimulating Mitochondria to Boost Long-Term Memory
An international team led by Jaime de Juan-Sanz at the Paris Brain Institute has shown that slightly increasing the metabolic capacity of neurons can enhance long-term memory in both fruit flies and mice. The study, published in Nature Metabolism...
02.24.2026 Research, science & health
Traitements anti-Alzheimer
Anti-Alzheimer Treatments: A Long-Term Beneficial Effect on Symptoms
There is currently no cure for Alzheimer's disease. The treatments available in France—which are not reimbursed—are known as symptomatic treatments, meaning that they act on the consequences of the disease rather than its underlying cause. In 2018...
02.19.2026 Research, science & health
État de mal épileptique
Status Epilepticus: New Insights Gained from National Health Data
The most severe form of epilepsy, status epilepticus is a high-risk neurological emergency. Yet its epidemiology remains poorly understood, particularly in France. By analyzing data from the French National Health Insurance system, compiled within...
02.19.2026 Research, science & health
Sclérose en plaques : identification d’une nouvelle molécule favorisant la remyélinisation
Multiple Sclerosis: Identification of a Molecule that Promotes Repair of the Nervous System
A molecule previously studied in the context of sleep disorders and attention deficit hyperactivity disorder (ADHD) is now, for the first time, revealing its potential in experimental models of multiple sclerosis (MS): it protects neurons and...
01.27.2026 Research, science & health
VignetteActu WBHF 2026
World Brain Health Forum 2026
More than one in three people will experience a brain disorder at some point in their lives. This reality, identified by the World Health Organization as a major public health priority, calls for unprecedented international mobilization. It is...
01.12.2026 Events
See all our news